SuperworthBIO-TECHNE market cap TECH
Share price times shares outstanding: what the whole company sells for, since 2010.
- Today, Oct 23, 2026
- $11.4B
- Highest close in our data
- $21.1B
- Sep 2021
BIO-TECHNE is worth $11.4B at the close on Oct 23, 2026, at $72.55 a share.
That is up 11% over the last year and down 44% over five years.
Its highest close in our data was $21.1B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $11.4B | $6.8B | $11.4B | +23% |
| 2025 | $9.2B | $7.3B | $12.2B | −20% |
| 2024 | $11.6B | $9.8B | $13.2B | −5% |
| 2023 | $12.2B | $9.1B | $14.1B | −6% |
| 2022 | $13B | $11.1B | $17.5B | −36% |
| 2021 | $20.3B | $12.5B | $21.1B | +66% |
| 2020 | $12.3B | $6.4B | $12.4B | +47% |
| 2019 | $8.3B | $5.5B | $8.5B | +55% |
| 2018 | $5.4B | $5B | $7.7B | +10% |
| 2017 | $4.9B | $3.7B | $5B | +26% |
| 2016 | $3.8B | $3.1B | $4.3B | +15% |
| 2015 | $3.3B | $3.2B | $4.1B | −5% |
| 2014 | $3.5B | $3.1B | $3.6B | +1% |
| 2013 | $3.5B | $2.4B | $3.5B | +38% |
| 2012 | $2.5B | $2.4B | $2.7B | −0% |
| 2011 | $2.5B | $2.3B | $3.1B | +4% |
| 2010 | $2.4B | $2.2B | $2.5B | n/a |
Against its peers
Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.
| Company | Market cap |
|---|---|
| TECHBIO-TECHNE | $11.4B |
| RGENRepligen | $10B |
| KRYSKrystal Biotech | $9.2B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| ONCBeOne Medicines | $42.9B |
| ADMAAdma Biologics | $2.4B |
| Peer median | $15.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on BIO-TECHNE
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.